Jefferies Group LLC Compass Pathways PLC Transaction History

Jefferies Group LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$11.13 - $23.04 $52,121 - $107,896	-4,683 Closed	0 $0
Q4 2021 Sep 21, 2023	SELL	$21.81 - $48.96 $142,702 - $320,345	-6,543 Reduced 58.28%	4,683 $103,000
Q4 2021 Feb 14, 2022	SELL	$21.81 - $48.96 $142,702 - $320,345	-6,543 Reduced 58.28%	4,683 $103,000
Q3 2021 Sep 21, 2023	SELL	$29.03 - $38.62 $4.24 Million - $5.64 Million	-146,019 Reduced 92.86%	11,226 $335,000
Q3 2021 Nov 15, 2021	BUY	$29.03 - $38.62 $325,890 - $433,548	11,226 New	11,226 $335,000
Q2 2021 Aug 16, 2021	SELL	$32.29 - $39.68 $5.08 Million - $6.24 Million	-157,245 Closed	0 $0
Q1 2021 Sep 21, 2023	SELL	$34.75 - $57.5 $13.8 Million - $22.8 Million	-397,003 Reduced 71.63%	157,245 $5.79 Million
Q1 2021 May 14, 2021	SELL	$34.75 - $57.5 $13.8 Million - $22.8 Million	-397,003 Reduced 71.63%	157,245 $5.79 Million
Q4 2020 Sep 21, 2023	BUY	$32.0 - $59.2 $17.7 Million - $32.8 Million	554,248 New	554,248 $26.4 Million
Q4 2020 Feb 16, 2021	BUY	$32.0 - $59.2 $7.13 Million - $13.2 Million	222,962 Added 67.3%	554,248 $26.4 Million
Q3 2020 Nov 13, 2020	BUY	$28.83 - $43.17 $9.55 Million - $14.3 Million	331,286 New	331,286 $11.6 Million

144

29.3M

156K

563K

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.